Researchers performed a pig‑to‑human kidney xenotransplant into a brain‑dead recipient and ran comprehensive multi‑omics and physiological monitoring over 61 days, revealing the immune dynamics that drive rejection and demonstrating reversal with approved immunomodulatory drugs. The work was published in Nature and represents an unprecedented longitudinal dataset bridging animal models and clinical translation. The teams tracked both antibody‑mediated and T‑cell–driven responses, mapped species‑specific gene expression in the graft, and identified signatures that preceded clinical rejection. Crucially, a combination of existing FDA‑approved agents suppressed the rejection process and restored graft function without permanent damage. Investigators say the data clarify mechanisms to anticipate and manage xenograft immune reactions in living recipients and provide a roadmap for future clinical trials of genetically edited pig organs. The study advances xenotransplantation from proof‑of‑concept to actionable clinical protocols.